相关实验视频
Updated: Jun 14, 2025

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
118
整合血p-tau217和数字认知评估,用于早期发现阿尔茨海默病
Casey R Vanderlip1, Craig E L Stark1
1Department of Neurobiology and Behavior, University of California Irvine, Irvine, California, USA.
概括
将化217 (p-tau217) 血测试与数字认知评估相结合,可以提升早期发现阿尔茨海默病 (AD) 风险. 这种方法可以准确地识别可能在五年内经历认知衰退的个体.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物研究 生物标志物研究
- 认知评估 认知评估
背景情况:
- 化的 (p-tau) 217是阿尔茨海默病 (AD) 的早期生物标志物.
- 在阿尔茨海默病的认知衰退时间有很大的差异.
- 数字认知评估可以检测到微妙的认知变化.
研究的目的:
- 评估将数字认知评估与p-tau217相结合是否可以改善对未来AD相关认知衰退风险的个体的检测.
- 评估这种综合方法的预测准确性.
主要方法:
- 对954名粉样蛋白阳性,认知不受损的个体进行分析.
- 使用数字认知评估和血p-tau217血液检测.
- 在5年内对临床前阿尔茨海默氏症认知复合 (PACC) 和迷你精神状态检查 (MMSE) 的下降预测评估.
主要成果:
- 数字认知评估和p-tau217的结合改善了拒绝PACC和MMSE的个体的识别.
- 这种综合方法在非脂蛋白E ε4非载体中显示出更强的预测价值.
- 预测值在性别上没有显著差异.
结论:
- 将血p-tau217与数字认知评估相结合,为识别患有AD相关认知衰退高风险的个体提供了一种敏感的方法.
- 这种方法实现了比单独测量更高的精度.
- 将血液测试与数字认知评估相结合,提供了一个可扩展和可行的AD查策略.
相关概念视频
Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170

